RecruitingNot ApplicableNCT06240208

Physical Inactivity and Appetite Regulation

The Effects of Inactivity on GLP-1 Stimulated Appetite Regulation in Healthy Normal Weight Males: A Randomised, Parallel Group Study

Sponsor

Rigshospitalet, Denmark

Enrollment

40 participants

Start Date

Mar 1, 2024

Study Type

INTERVENTIONAL

Conditions

Overweight

Summary

The goal of this parallel-group, two-arm, assessor-blinded, randomised clinical trial is to investigate the effects of reducing physical activity on food intake and satiety in physically active and healthy males, 40-55 years of age. The main questions it aims to answer are: * Does physical inactivity affect GLP-1 stimulated food intake? * Does physical inactivity affect food preferences, satiety and other mechanisms supporting appetite regulation? Participants will be randomised (1:1) to two weeks of either no intervention (control group) or inactivity. Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day. Researchers will compare the inactivity group to the control group to see if physical inactivity impairs appetite regulation.

Eligibility

Sex: MALEMin Age: 40 YearsMax Age: 55 Years

Inclusion Criteria26

Male
Age ≥ 40 years and ≤ 55 years
Body mass index (BMI) > 20 and < 25 kg/m2
Physical activity level should as a minimum include: Active commuting by biking a minimum of 10 km, four days per week or an equivalent amount of other physical activity four days per week.
Healthy (based on self-reporting, pre-study medical examination and biochemical screening)
Can adhere to two weeks of inactivity (refrain from running, cycling and all other exercise while reducing steps to max. 1500 pr. day)
Caucasian
No change in body weight > 5 kg within the last 6 months
Eats breakfast and lunch daily
Does not follow specific dietary restrictions
No disliking of spaghetti bolognese
No diagnosis of psychiatric disorder or treatment with anti-depressant or anti-psychotic medication
No history of suicidal behavior or ideations.
No previous surgical treatment for obesity
No cardiovascular disease
No rheumatologic disease
No metabolic/endocrine disease
No liver disease (ASAT or ALAT >2x upper normal range)
No other chronic disease
No elite sports
No frequent or chronic use of medications affecting bodyweight, physical performance, or inflammation (NSAIDS, DMARDS, corticosteroids)
No current infection
No history of cancer
No anemia (hematocrit <33%)
No smoking
No participation in other research intervention studies

Exclusion Criteria4

Clinical or biochemical signs of disease
HbA1c > 39 mmol/mol
Unable to allocate the needed time to fulfill the intervention
Language barrier, mental incapacity, unwillingness, or inability to understand and be able to complete the interventions

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALInactivity

Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.